Biotech Stocks

AXSM News: Why Axsome Therapeutics Stock Is Skyrocketing
Axsome Therapeutics (NASDAQ:AXSM) stock was flying high on Monday following some good AXSM news. The new bit of AXSM news from the company that has Axsome Therapeutics stock on the rise today has to do with recent results from a study. This comes from a Phase 2 trial of using its AXS-05 to treat major depressive disorder. The Phase […]

4 Strong Buy Biotech Stocks With Upcoming FDA Decisions
It’s crunch time. These 4 biotechs have what it takes to score crucial regulatory approvals Biotech stocks live and die by FDA decisions. Shares can soar or plunge depending on the FDA decision. Even an approval can spark a selloff if it’s not what investors expect. All four biotech stocks below have a fast-approaching PDUFA date. […]

Fortress Biotech: A Unique Company Aiming To Make A Big Impact In Medicine
Note: This is a review of Fortress Biotech as a company. Do your own research before making any investment decisions. The biopharmaceutical industry is at the forefront of developing the healthcare solutions of tomorrow. One interesting company, Fortress Biotech (FBIO), has taken a unique and different approach to drug discovery and drug development. Fortress Biotech’s business model […]

7 Cheap Biotech Stocks To Buy Now
These biotech stocks are set for a strong comeback as investors walk away from large-cap tech companies U.S equities largely treaded water on Wednesday as Wall Street reacted to legal events and President Trump’s somewhat muted reaction to them. Elsewhere, strong earnings out of the retail sector are helping boost sentiment. The release of the […]

5 Clinical-Stage Biotech Stocks To Buy Under $10
Clinical-stage biotech stocks offer plenty of promise to investors looking to take on some risk Not many sectors offer the potential for big time gains like biotech. Especially when you’re looking at smaller clinical-stage names. After all, the thrill of getting a big-time approval or even making through to the next round of FDA trial […]

5 Big Biotech Stocks To Buy Under $10
Small biotech stocks can pack a wallop For investors, biotech stocks remain one of the most dynamic sectors out there. On one hand, you have some of the largest pharmaceutical firms on the planet with multi-billion-dollar blockbuster drugs filling their coffers. On the other, you have the more stereotypical “lotto ticket” biotech stocks of clinical […]

4 Triple-Digit Winners In Biotech
With important catalysts coming up in 2017, these stocks could soon become triple-digit winners in your portfolio. Start building a well-diversified biotech portfolio with these four stocks. The overall biotech sector continues to be locked in a tight trading range, especially for such a high beta sector of the market. First quarter earnings reports for […]

3 Undervalued Stocks On The Verge Of A Breakout
Buying shares at these prices might look like a gift in six month’s time. With multiple catalysts to fuel share price growth on the horizon and a lot of good news not yet baked into the share price, now is a great time to get in. The fairy tale story for biotech investors is buying […]

3 Small Biotech Moonshots To Add To Your Portfolio
As the biotech sector heats up more in 2017, small stocks like the three in this article have already turned in some stellar performances. With the entire sector gaining steam, there’s still plenty of upside left. Bret Jensen recommends adding these three stocks to the portfolio. Sentiment on the biotech sector early in 2017 sure has […]

3 Biotech Stock Beneficiaries Of A Streamlined FDA
With lower approval wait times and decreased regulations on the horizon, long-term investing opportunities in the biotech sector haven’t looked this great in over two years. Take a look at these three stocks in particular as they will reap the most reward from a streamlined FDA. After an approximate gain of 10% in February, the […]

3 Attractive Growth Stocks With Near-Term Catalysts
The market is off to a much stronger start this year than the bloodbath equities were greeted with to begin 2016. Biotech, after a dismal 18 months of underperformance is no exception. Sentiment on this beaten down part of the market started to improve immediately after the unexpected election result in November. The specter of […]